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Therapeutic mammaplasty allows breast conservation and maintains breast cosmesis in women with
larger and ptotic breasts. They are associated with more post-operative complications, potentially
delaying adjuvant treatment. Our aim is to investigate the impact of therapeutic mammaplasty on the
timing of adjuvant chemotherapy, compared with conventional breast conservation surgery.
Methods: Retrospective data collection of breast cancer patients undergoing breast-conserving surgery at
a single institution from 2009 to 2013.
Results: 1000 patients underwent breast-conserving surgery, 40 underwent therapeutic mammaplasty.
Patients with a complication of mammaplasty had no delay to starting chemotherapy compared to those
without complication (median 36 vs. 40 days). There was no delay to chemotherapy for patients
requiring further breast cancer excision surgery following therapeutic mammaplasty compared with
standard breast conservation surgery (36 vs. 39 days).
Conclusions: There is no delay in commencing adjuvant chemotherapy following therapeutic mamma-
plasty surgery, even if there is a complication of surgery. However, patients with involved margins had a
signiﬁcant delay to chemotherapy whilst awaiting re-excision surgery.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Oncoplastic breast techniques are being increasingly employed
to allow breast conservation whilst maintaining a quality
aesthetic outcome. Therapeutic mammaplasty (TM) describes
multiple breast-conserving techniques1 which remove the breast
tumour in combination with adjuvant radiotherapy. TM is avail-
able to women with early stage breast cancer with larger or ptotic
breasts who would beneﬁt from a reduction mammaplasty
technique in addition to tumour removal. The use of TM is
increasing worldwide, with the potential to deliver beneﬁts both
oncologically, in terms of increased tumour free margin width,
and with an associated superior long-term aesthetic outcome.2,3
Despite increasing enthusiasm for the techniques there is
limited data on long-term oncological safety or effects upon de-
livery of adjuvant treatments.4,5 TM techniques can enable a
larger volume of tissue to be resected with the tumour6 enabling
patients to have breast-conserving surgery for larger tumours.
Just as the role of TM is expanding, adjuvant chemotherapy isrsity Hospital of South Man-
Manchester M23 9LT, UK.
rvey).
ciates Ltd. Published by Elsevier Ltincreasingly being used in women with early stage breast cancer7
and if delivered in a timely fashion after the primary resection,
decreases recurrence and improves overall survival.8 However,
TM is associated with higher complication rates than traditional
breast-conserving methods and one barrier to TM is the concern
that post-operative complications may lead to a delay in initiation
of chemotherapy or even omission.9 There is increasing evidence
that immediate breast reconstruction has an effect on adjuvant
chemotherapy delivery. Three recent series involving over 4000
patients suggest that immediate breast reconstruction does lead
to a signiﬁcant delay in the delivery of adjuvant chemotherapy.10e
12 However, the clinical signiﬁcance of this delay has not been
established.10 On the contrary, a recent study performed by
Doughty et al. compared 95 patients undergoing immediate
breast reconstruction following mastectomy with cohorts having
breast-conserving surgery and simple mastectomy with no
reconstruction, in which no delay to commencement of adjuvant
chemotherapy was noted.13
Themajority of case series on TM do not comment on the timing
of adjuvant treatments. When they are reported, studies vary be-
tween no delays to adjuvant treatment through to ﬁve studies
reporting delays in between 1.9%9 and 6% of patients.14 The purpose
of this study was to examine the impact of TM on the delivery of
adjuvant chemotherapy.d. All rights reserved.
Table 1
Patient speciﬁc data for 40 patients undergoing therapeutic mammaplasty.
Tumour Grade/Her 2 Tumour size (mm) Margin (mm) Complications Further surgery Time to CT from ﬁrst surgery (days)
IDC 3/D 35 0 e mx & ibr 35d
DCIS / 80 0 Haematoma, delayed healing mx & ibr e
ILC 3/ 110 0 Haematoma, infection mx & ibr 64
IDC 3/ 32 0 e reex 78
IDC 3/ 19 0 e e 33
IDC D DCIS 2/L 20 0 e reex & ANC 64
IDC 3/ 30 0.3 Skin & nipple necrosis contralat mx 74
Tubular 1/ 11 0.9 Delayed healing e e
IDC 2/þ 19 <1 e reex e
pLCISe 2/þ 21 <1 Delayed healing ANC e
IDCa 2/L 35 1 e e 30
IDC þ DCIS 3/þ 32 1 e e 57
Mucinous 1/ 20 1.2 Delayed healing e e
IDC 3/ 13 1.3 Delayed healing e e
IDC 2/ 17 1.5 e e 52
IDC 3/D 40 1.5 e e n/ac
IDC 3/þ 21 1.5 e e 24
Mucinous 1/ 40 1.5 Delayed healing e e
pLCISe 2/þ 6 1.5 e e e
DCIS / 30 2.8 Delayed healing e e
IDC 1/L 18 4 e e e
IDC 3/ 27 5 e e 50
IDC þ DCIS 3/þ 20 5 Skin necrosis Debridement 33
IDC 3/ 13 5 e e 40
DCIS / 80 5 Delayed healing e e
IDC 2/L 25 5 e e e
IDC 3/ 30 5 e e 26
IDC 3/ 18 5 e e e
IDC 3/ 14 5 e e e
IDC 3/ 16 5 e e e
IDC 2/L 23 5 e e e
IDC 3/ 14 5 e e e
DCISa / 20 6 e e e
IDC 2/ 16 10 Fat necrosis e 36
IDC 3/þ 25 10 Delayed healing ANC 47
IDC 3/D 33 10 e e 37
Metaplastic 3/þ 25 10 e e n/ab
IDC 1/ 11 10 e e e
IDC 3/þ 40 10 e e 43
DCIS 1/ 5.5 10 e e e
IDC 1/L 11 10 e e e
IDCe invasive ductal carcinoma, ILCe invasive lobular carcinoma, DCISe ductal carcinoma-in-situ, pLCISe pleomorphic lobular carcinoma-in-situ, CTe chemotherapy. Mxe
mastectomy, ibr e immediate breast reconstruction, reex e re-excision of margins, anc e axillary node clearance.
a Neoadjuvant letrozole.
b Patient moved out of region for adjuvant therapy.
c Patient declined all adjuvant treatment.
d Patient had adjuvant chemotherapy prior to completion surgery.
e Bilateral operations.
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A retrospective review of our database of all women who un-
derwent breast-conserving surgery for breast cancer between
January 2009 and March 2013 was performed. A total of 1000
womenwho underwent breast-conserving surgery (wle) for breast
cancer were identiﬁed. 40 women had a therapeutic mammaplasty
performed as their primary surgery. Patients were pre-operatively
counselled that given the position and size of the cancer, if
treated with conventional breast-conserving surgery the ﬁnal
cosmetic result may be compromised. All patients underwent a
pre-operative consent process detailing the advantages and po-
tential disadvantages of TM.
2.1. Surgical methodology
During the planning process, women were assessed for breast
volume, degree of ptosis, lesion size and location, previous breast
surgery and suitability for radiotherapy. Patients underwent pre-
operative ultrasound assessment of the axilla. The axilla wastreated with sentinel node biopsy if the pre-operative ultrasound
scan þ/ ﬁne needle aspirate was benign, and axillary clearance if
the ﬁne needle aspirate was positive for malignant cells. Cancers in
the superior pole of the breast were treated with an inferior pedicle
based technique, cancer in the inferior pole of the breast were
treated with a superior pedicle technique. Central tumours were
treated with a Grisotti ﬂap or a wedged excision technique. In some
cases, two pedicle techniques were employed e with the second
pedicle used to ﬁll defects in the upper inner or upper outer
quadrants. Larger breasts underwent wise pattern skin reduction,
small and medium sized breasts were treated with periareolar,
vertical scar or comma shaped incisions.
Operations were performed by six consultant breast surgeons
using wire guidance localisation for impalpable lesions. Resected
specimens were orientated intra-operatively for pathology and
underwent intra-operative specimen radiology to assess margin
adequacy. Four quadrant cavity shave biopsies were taken from the
remaining breast parenchyma. Metallic clips were left to identify
the breast surfaces adjacent to the tumour bed. Deﬁnitive pathol-
ogy was reviewed and patients with involved radial margins were
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anterior and posterior margins were reviewed and did not have re-
excision if the margin could not be improved upon.
Following surgical treatment and chemotherapy (as required)
all patients were offered adjuvant radiotherapy, with a boost to the
tumour bed if patients had an increased risk of local recurrence.
Follow-up was performed with annual clinical and mammographic
surveillance for ﬁve years.
The data on TM patients was compared to a cohort of patients
undergoing breast conservation surgery who received adjuvant
chemotherapy, and, patients who had conservation surgery and re-
excision of margins followed by adjuvant chemotherapy during the
same time period.
Statistical analysis e Non-paired two-tailed student t-test was
used to determine any signiﬁcant difference in the time period
between surgery and commencement of adjuvant treatment be-
tween groups. Patients having neo-adjuvant chemotherapy were
excluded from the statistical analysis.
3. Results
3.1. Therapeutic mammaplasty population
40 patients (41 breasts) underwent therapeutic mammaplasty
(see Table 1). This procedure is increasing in frequency year on year,
with ﬁve procedures performed in 2009, two in 2010, 13 in 2011
and 16 in 2012. One cancer was bilateral, all other being unilateral,
22 of which were screen detected and 18 were symptomatic can-
cers. They were followed up for 17 months (range 2e35 months).
Median age was 53 (range 35e67). Mean tumour size was 27 mm
(range 6e110).
3.2. Tumour characteristics
19 tumours had wire localisation, three had an ultrasound
skin marker localisation and all other tumours were palpable.
Seven tumours were staged as pTis, no tumours were pT1aeb, 15
were pT1c, 18 were pT2, one was pT3. Three breasts with DCIS
alone had no nodal assessment. 31 breasts had nodal status pN0,
one patient was pN1mi, four patients were pN1, one patient was
pN2 and one patient was pN3. Two patients had neoadjuvant
letrozole and one patient neoadjuvant chemotherapy prior to
resection. 20 patients had a synchronous contralateral breastTable 2
The length of time taken for patients to receive the ﬁrst adjuvant chemotherapy
treatment from the date of ﬁrst surgery and from completion of surgery. Median
wait is shown  standard error. Patients in whom a re-excision (both wle and TM
group) is required from involved surgical margins have a signiﬁcantly longer period
until delivery of the ﬁrst treatment. The presence of a post-operative complication in
the TM doesn’t alter the length of time the patient has to wait for the ﬁrst chemo-
therapy treatment.
wle wle þ
re-excision
TM TM þ
complication
TM þ
re-excision
n 224 35 18 3 5
Median wait
from 1st
operation to
adjuvant
chemotherapy
37  1 66  4 40  3 36  4 64  8
Median wait from
completion
of surgery to
adjuvant
chemotherapya
37  1 39  3 40  3 36  4 36  1
a Patients having chemotherapy prior to re-excision were excluded from the
analysis.reduction, two patients had a delayed contralateral reduction
and one went on to have bilateral mastectomies and implant
based reconstructions.
3.3. Margins and oncological outcomes
Mean specimen weight was 347 g (range 10e1398), the 10 g
mammaplasty was primarily excision of skin redundancy rather
than volume reduction. Clear excision margins of 2 or more mm
were achieved in 54% (22) of breasts, 32% (13) with<2mm and 15%
(6) had a pathologically involved margin. Of those with a patho-
logically involved margin, three patients had mastectomy and im-
mediate reconstruction, two had re-excision of the margin and one
patient with an involved anterior margin had radiotherapy alone.
One patient had a contralateral mastectomy and reconstruction due
to DCIS in the breast reduction specimen with an involved margin
adjacent to the pedicle supplying the nipple areola complex (NAC).
There was no correlation between specimen weight and positive/
close margins.
3.4. Complications
Complications included one haematoma requiring evacuation,
one haematoma treated conservatively, and one breast with nipple
necrosis requiring debridement, one breast with skin necrosis
requiring debridement in out-patients, nine breasts with delayed
wound healing (T-junction) and one patient with signiﬁcant fat
necrosis. The overall complication rate was 37% per breast.
3.5. Timing of chemotherapy
1000 patients underwent breast-conserving surgery for breast
cancer, 960 underwent breast conservation surgery (wide local
excision e wle) and 40 underwent therapeutic mammaplasty. Of
960 patients undergoing wle, 259 patients had adjuvant chemo-
therapy following initial resection. 35 patients requiring re-excision
surgery underwent adjuvant chemotherapy, eight patients received
chemotherapy prior to re-excision and 27 following re-excision of
margins after initial wle. Time to chemotherapy for each surgical
group is shown in Table 2. The median time to commencement of
chemotherapywas 37 days in thewle group (Fig.1), compared to 39
for those having wle and re-excision surgery (p ¼ 0.96).
In the therapeutic mammaplasty group e 18 patients received
post-operative adjuvant chemotherapy. The median wait to
chemotherapy was 40 days (range 24e78). Patients with clear
margins and no complications had a median wait until chemo-
therapy of 40 (range 24e52) days. Patients in whom a post-oper-
ative complication occurred (n ¼ 3), even if it required further
surgery, had no delay to the start of chemotherapy (p 0.93), with a
median wait of 36 days (range 33e47). TM patients with involved
margins requiring re-excision (n ¼ 5) had a signiﬁcant delay to
starting adjuvant chemotherapy from the time of the ﬁrst operation
(medianwait of 64 days, range 35e78) comparedwith those having
wle alone and those having TM requiring no re-excision (p ¼ 0.03).
There was no delay in adjuvant chemotherapy from the date of
completion of surgery (36 days TM re-excision vs. 40 days TM
alone, p ¼ 0.41). Waiting times for TM patients requiring re-
excision were similar to those having re-excision after wle sur-
gery (median 36 vs. 39 days, p¼ 0.43). One patient with an involved
margin underwent adjuvant chemotherapy prior to completion
breast surgery; this patient was included in the statistical analysis.
37 patients had adjuvant radiotherapy, of the three patients who
did not have radiotherapy; one had a completion mastectomy with
clear margins not requiring radiotherapy and two patients declined
radiotherapy.
Fig. 1. Waiting time to adjuvant chemotherapy. The median waiting time from surgery to the start of adjuvant chemotherapy is shown for both Wide Local Excision (WLE) and
Therapeutic Mammaplasty (TM). The wait time from completion of surgery to chemotherapy is consistent across all groups (hatched column). For those requiring re-excision
surgery there is a signiﬁcantly longer wait from the date of the ﬁrst operation (shaded column) to starting chemotherapy, caused by the need for further surgery.
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Since the introduction of oncoplastic breast surgical techniques
there has been considerable concern from within the breast sur-
gical community that oncological safety may be compromised.15
Immediate breast reconstruction is associated with a modest
delay to receiving adjuvant chemotherapy.10e12 Delays beyond 12
weeks (84 days) are associated with a poorer outcome both in
terms of relapse free survival and overall survival.8 Current UK NICE
guidance suggests that adjuvant chemotherapy should begin
within 31 days of completion of surgery.16 The rate of adjuvant
chemotherapy following wle was 26.9% in our combined symp-
tomatic and screen-detected series. This rate of adjuvant chemo-
therapy is consistent with the National ﬁgure of 27.4% in
symptomatic and 18.2% in screen-detected cancers.17 The rate of
chemotherapy in our TM patients was 45%, this is signiﬁcantly
higher due to the higher stage of tumour treated with TM. One
advantage of TM is the potential to increase tumour free margin
width in breast-conserving surgery. Rates of involved margins
range from 0% in series of 11,18 619 and 63 patients20 to 36%21 with
an average of 13% (188/1427) of cases reported.2,3,6,9,14,18e32
Although most studies accept margins over 2 mm, two studies
accept margins of 1 mm21,29 and two studies if macroscopically
clear even if<2mm.3,6 The involved margin rate (<1mm) of 15% in
our series is similar to that previously described, but 46% of patients
had a margin <2 mm which is high compared to the published
literature. Our unit guidance is for a margin of 1 mm, so this is the
target for which our surgeons aim intra-operatively. The presence
of an involved margin led to a signiﬁcant delay to starting
chemotherapy from the time of the ﬁrst operation compared to
those with clear margins; 64 days vs. 40 days. A delay is likely in
this situation due to the requirement of further resection to clear
margins or mastectomy þ/ reconstruction prior to adjuvant
treatment. The cause of delay in our series is the wait for deﬁnitive
pathology after primary surgery with subsequent MDT discussion,
the time taken tomake treatment decisions with the patient as well
as waiting time for a second operation followed by a period of re-
covery prior to chemotherapy. There was no signiﬁcant delay to
adjuvant chemotherapy from time to completion of TM surgery.
The median wait from second operation to chemotherapy was 36
days, exceeding the NICE recommendation of 31 days. This is a
small delay the clinical signiﬁcance of which is unknown. The
waiting time to adjuvant chemotherapy in TM patients is similar to
that of patients having standard wide local excision surgery.
Therefore, the surgery itself does not delay adjuvant chemotherapy,however, in our series there is a small delay to adjuvant chemo-
therapy in all groups when compared to NICE guidance. This is a
multifactorial problem in a large tertiary referral unit and over the
course of this case series there is a gradual improvement in this
waiting period year on year. Our waiting time for adjuvant
chemotherapy are similar to prior series which show average
waiting times of 29, 38 and 40 days.12,13,33 The ﬁnding of no sig-
niﬁcant delay to adjuvant chemotherapy is consistent with recent
data published on a series of Oncoplastic Breast Conserving Surgery
(OBCS) techniques, which included a mixed group of 31 patients
undergoing TM or volume replacement surgery.34 The median time
to chemotherapy in this series was 29 days after OBCS and 29.5
days after wle.34
In our series, those undergoing TMwho had a complication from
the primary surgery had no delay to starting adjuvant chemo-
therapy. This is in keeping with multiple previous case series of TM.
The majority of complications associated with TM in all series are
mild including fat necrosis, delayed wound healing and infections.5
The majority of these are likely to be well healed prior to adjuvant
therapy and therefore will only occasionally delay treatment.9,14
The management of an involved margin in this series was
further re-excision to ensure clear margins prior to adjuvant
radiotherapy. Whole breast radiotherapy is the standard of care
when the breast is conserved, however, management of a close
margin following TM varies. Management can include re-exci-
sion,9,23 radiotherapy boost to tumour bed9,14 or no further treat-
ment.2 Analysis of margins intra-operatively with frozen section
may reduce the need for re-excision, but this does require local
histopathological or cytological expertise and availability.35
One patient in our series had DCIS found in the breast reduction
specimen in the contralateral breast. DCIS was present at the
margin adjacent to the pedicle supplying the nipple areola complex
(NAC), for which a further re-excision of margins was deemed
inappropriate and a subsequent skin sparing mastectomy and im-
mediate breast reconstruction was performed. The risk of carci-
noma in breast reduction specimens is low, approximately 0.3% of
breast reduction specimens contain an incidental cancer.36 Patients
should be counselled for this risk and specimens orientated intra-
operatively.
Limitations to this study include its observational nature on a
small population group. There are few large cohorts of women
undergoing TM,5 probably due to a lack of expertise, lack of data
collection and a low frequency of using the operation as primary
cancer surgery. Despite the small numbers involved there is a very
signiﬁcant delay from the date of the ﬁrst operation to the start to
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With the increase in use of TM there will be large numbers of units
performing relatively few of these procedures on an annual basis;
the results of this study are relevant to all units performing the
procedure. Units should audit their own data and plan the patient
journey for those patients requiring re-operation so that delays are
eliminated or minimised. An alternative pathway is for patients to
have adjuvant chemotherapy after their primary surgery and before
completion surgery, to avoid delay. This policy was used for one of
our patients who started adjuvant chemotherapy 35 days after
primary surgery compared to 64, 64, 68 and 78 days for the patients
receiving their completion surgery prior to starting chemotherapy.
5. Conclusion
In conclusion, our study provides evidence that TM does not
lead to a delay in the commencement of adjuvant chemotherapy
when compared to an adequate control group. There was no rela-
tionship between post-operative complications and delay to
chemotherapy. Patients who wish to undergo TM must be coun-
selled about the potential delay to adjuvant chemotherapy associ-
ated with inadequate primary excision margins, where re-excision
occurs prior to chemotherapy. A streamlining of the service with
expediting of the second operation and subsequent chemotherapy
may avoid signiﬁcant delay, or administration of chemotherapy
prior to completion surgery.
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